DPP4 and metabolic syndrome: Similarly, DPP-4 inhibitors (HR, 0.707; 95% CI, 0.572–0.874; P = 0.001), dyslipidemia (HR, 0.710; 95% CI, 0.551–0.915; P = 0.008), and ACEI/ARBs (HR, 0.622; 95% CI, 0.446–0.868; P = 0.005) reduced the risk of eGFR decline >30% (Figure 4C).